Form D · Biotechnology
Aravive, Inc.
Houston, TX · CIK 0001513818
Offering snapshot reported Oct 28, 2022 · SEC filing
- Reported sold
- $41.6M Offering amount: $41.6M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 27, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 28, 2022 | Initial | $41,560,000 | No comparison | 17 | SEC filing |
| Feb 20, 2014 | Initial | $54,999,991 | No comparison | 19 | SEC filing |
| Feb 19, 2014 | Initial | $10,000,000 | No comparison | 10 | SEC filing |
| Oct 11, 2013 | Initial | $9,999,999 | No comparison | 10 | SEC filing |
| Jul 22, 2013 | Initial | $12,499,999 | No comparison | 7 | SEC filing |
| Jan 28, 2013 | Initial | $4,587,998 | No comparison | 6 | SEC filing |
| Jan 28, 2013 | Initial | $7,999,999 | No comparison | 7 | SEC filing |
| Mar 9, 2011 | Initial | $14,419,861 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.15M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-463217
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| MTS Securities, LLC | 104059 |
Source: Form D, filed Oct 28, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Srinivas Akkaraju | Director |
| Joshua Brumm | Executive |
| Jeffrey Cleland | Director, Executive |
| Francesco De Rubertis | Director |
| Leonard Scott Dove | Executive |
| Michael Dybbs | Director |
| Fredric N. Eshelman | Director, Executive |
| Robert B. Geller | Executive |
| Amato Giaccia | Director |
| Peter T.C. Ho | Director |
| John A. Hohnecker | Director |
| Rudy Howard | Executive |
| Edmon Jennings | Director |
| Kevin Johnson | Director |
| Sigurd C. Kirk | Director |
| Shahzad Malik | Director |
| Gail Mc Intyre | Director, Executive |
| Michael W. Rogers | Director |
| Volker Schellenberger | Director |
| Jay Shepard | Director |
| Willem Stemmer | Director |
| Anthony Sun | Director |
| Paul Westberg | Executive |
| Eric Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3730 Kirby Drive Suite 1200
Houston, TX, 77098
Houston, TX, 77098